MiNK Therapeutics (INKT) to Release Earnings on Thursday

MiNK Therapeutics (NASDAQ:INKT) is set to announce its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

MiNK Therapeutics (NASDAQ:INKT) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts expect MiNK Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

MiNK Therapeutics Trading Up 4.0 %

Shares of INKT stock opened at $0.78 on Wednesday. MiNK Therapeutics has a 12-month low of $0.57 and a 12-month high of $1.90. The stock has a market capitalization of $30.84 million, a P/E ratio of -1.59 and a beta of 0.05. The firm’s 50 day moving average is $0.73 and its 200 day moving average is $0.86.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 target price on shares of MiNK Therapeutics in a research report on Wednesday, October 9th.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.